Background: The pathophysiology of brain injury following aneurysmal subarachnoid haemorrhage (SAH) is associated with numerous mediators. The aim of the study is to analyse protein changes after SAH in cerebrospinal fluid (CSF) using mass spectrometry (MS). Methods: CSF samples were obtained from forty-four control subjects, seven good outcome and ten poor outcome SAH patients. CSF samples were collected at specific time intervals after SAH (days 1, 5 and 10). MALDI-TOF (Matrix Assisted Laser Desorption/Ionization Time-of-Flight) and ClinProTools software were utilised for MS, MS/MS (Mass Spectrometry) spectra collection and analysis. Selected masses were identified. The MALDI-TOF profiling experiments allowed for the targeted selection of potential markers in SAH. The study was performed in three steps by comparison of CSF samples: (1) from the control group and SAH patients (both good and poor outcome groups); (2) collected on days 1, 5 and 10 within the groups of poor SAH and good SAH patients, respectively; (3) from poor outcome SAH and good outcome patients at days 1, 5 and 10. Results: 15 new proteins whose CSF level is alternated by SAH presence, SAH treatment outcome and time passed since aneurysm rupture were identified. Conclusions: We demonstrated new proteins which might play a role in different stages of subarachnoid haemorrhage and could be a new target for further investigation.
Introduction
The global incidence of aneurysmal subarachnoid haemorrhage (SAH) is 6.67 per 100,000 persons, and nearly half a million individuals suffer from SAH each year [1] . Approximately 15% will die before reaching the hospital, 25% die within 24 hours, and 45% die within 30 days. Only onethird will make a full recovery after treatment [2] . SAH is associated with a variety of pathological changes affecting both glial and neuronal brain cells. In patients with SAH, neurological dysfunction presents within several hours of injury. This decline was initially attributed to the progressive mass effect secondary to acute SAH; however, current evidence suggests that the progression to cerebral ischaemia is far more complex [3] . Interest has grown around early brain injury (EBI), which by definition covers all the pathophysiological processes occurring in the first 72 hours, including cortical spreading depression, microvascular injury, blood-brain barrier disruption, neuroinflammation and global cerebral oedema [4] . Recent evidence points to neuroinflammation as a key mediator of injury expansion and behavioural deficits [5] . The underlying mechanisms contributing to injury expansion following SAH are poorly understood, thereby limiting the number of effective pharmaceutical treatment options [6] [7] [8] . Changes in protein expression may provide more meaningful information regarding the complex mechanisms underlying neurological injury following SAH. Over the past several decades, a variety of proteins have been tested as therapeutic targets [9] . Unfortunately, despite showing great promise in the course of preclinical trials, most experimental drugs fail to lead to significant improvement in the outcome of patients with SAH [6, [9] [10] [11] [12] . Thus far, the only medication which has been shown to reduce cerebral infarction and improve outcome after SAH is nimodipine [13] . Therefore, a new approach is required to investigate the pathophysiology at the molecular and cellular levels in the hope of finding novel therapeutic targets [4, 14] . This paper is a preliminary study 
Methods

Ethics and Consent
This is a prospective observational study conducted at a single medical centre in accordance with the Declaration of Helsinki. The study was approved by the Local Bioethics Committee (approval no 983/13). The Local Bioethics Committee approved the study protocol, consenting protocol and consent forms. Either the patient or the next of kin gave consent for entry to the study, and the use of blinded medical data for analysis and publication.
Management, Definitions, End points
assess the presence of acute hydrocephalus.
EVD was placed following endovascular treatment in patients with GCS score below 15 and radiological markers of hydrocephalus.
A second CT scan was performed within 24 hours of aneurysm occlusion and EVD placement to assess any procedure related to brain injury. Patients received a continuous infusion of nimodipine for at least ten days; hypotension was avoided using vasopressors, and euvolemia was maintained. EVD infection screening involved CSF cell count at least twice per patient, and CSF culture at least once on day ten post-SAH. The primary endpoint was the treatment outcome assessed at three months using the Glasgow Outcome Scale (GOS) [17] . Patients were divided into two groups according to GOS. Good outcome (GO-SAH) consisted of those with no disability, moderate disability and severe disability (GOS grade 5, 4 and 3); poor outcome (PO-SAH) were those with persistent vegetative state or death (GOS grade 2 and 1). We decided to divide patients in such outcome fashion as we wanted to demonstrate the most extreme values in poor outcome treatment. Delayed cerebral ischaemia (DCI) related infarction was defined as a new cerebral infarction identified on a head CT scan within six weeks of rupture and not present on the immediate post-treatment scan (as proposed by Vergouwen [18] ).
Population, Inclusion and Exclusion Criteria
The analysed group consisted of 17 SAH patients (9 males and 8 females, mean age 60,9 years). There were seven good outcome patients (3 males and 4 females, mean age 60,42 years) and ten poor outcome patients (6 males and 4 females, mean age 62 years).
Control group consisted of 44 subjects with mean age 56,1 years. CSF samples were obtained during spinal anaesthesia from age and sex-matched patients (p = 0.56 and p = 0.68, respectively) with a negative history of CNS disease. There were 5 patients with the aneurysm located at the middle cerebral artery Sample processing, MALDI-TOF analysis and profiling studies The detailed sample processing procedure is attached in Supplementary Material 1.
Analyzed groups
Statistical analysis of experimental MS data was divided and performed in three separate steps: 
Results
Proteomic findings. 
SAH patients vs control group.
CSF proteins showing significantly different levels between SAH patients and the control group are amyloid like protein, transthyretin, augurin, and histatin 3 protein ( Table 3 ). The levels of amyloid like protein and transthyretin were increased in the SAH patients, whilst those of augurin and histatin 3 were decreased ( Figure 2 ).
Good outcome SAH patients vs. control group.
Comparison of CSF samples of GO-SAH patients with the control group showed significant differences for: augurin, synaptotagmin-11 protein and transthyretin ( Table 3 ). The transthyretin level was increased in the GO-SAH group, whilst the levels of augurin and synaptotagmin-11 were decreased (Figure 3 ).
Poor outcome SAH patients vs. control group.
When samples from the PO-SAH group were compared with the controls, the following peaks 
Comparison between good and poor outcome SAH patients on days 1, 5, 10.
Comparison of samples taken on all three collection days between the good and poor outcome patients identified complement C3 and histatin 3 (Table 5 ); the former was increased in the poor outcome group, whilst the latter was reduced (Figure 4 ).
Comparison on day one.
When the comparison was restricted to day 1, three proteins were identified: angiotensinogen, complement component C3 and secretogranin.
Angiotensinogen was elevated in the good outcome patients and complement C3 and secretogranin were elevated in the poor outcome group (Table 5, Figure 4 ).
Comparison on days 5 and 10. 
Discussion
There are many gaps in our understanding of the pathophysiology of SAH, and in particular of ways to predict and prevent the development of cerebral ischaemia [19] .
Numerous groups, including our own, have embarked on the analysis of alterations of a variety of proteins in biological fluids with this aim in view. Our previous studies on sTLR 2 and 4 [20] , sRAGE [21] and Clusterin [22] in CSF of Below, we present a brief commentary on those proteins which we feel likely to be most important. Transthyretin (TTR) is the most widely described protein in the group. On a cellular level, it is harmful to cell survival following an ischaemic insult to the brain [24] .
Patients suffering from an ischaemic stroke with an unfavourable outcome were found to have significantly lower TTR serum levels on admission [25] . On the contrary, TTR levels appear to be a negative predictor of poor outcome at three months following SAH [26] .
In the present study, we found a significant increase in TTR levels in SAH patients compared with healthy controls, but no clear difference between good and poor outcome patients at any point. Histatin 3 forms part of the innate immune system and is currently thought that its main function is to limit infections in the oral cavity [27] . Histatin 3 inhibits NF-kB activation in both TLR4/MD2/CD14 and TLR2/CD14 mode [27] ; no previous work has demonstrated its presence in CSF. In the current study, histatin 3 levels were significantly decreased in SAH patients, and also, the levels were significantly lower in the poor outcome group than in the good. Based on the available literature and our findings, we might speculate that CSF histatin 3 has a protective role in SAH pathophysiology. Augurin is a hormone-like protein that is thought to play a role in central nervous system (CNS) homeostasis [28] [29] [30] [31] .
A decrease in augurin protein occurs at times when cells proliferate in the normal CNS injury response. The time-course of decreased augurin correlates with the acute and subacute response times to CNS injury as both gene and protein expression are decreased at 1-3 days post injury, but return to uninjured levels by day 7 [32] . Our study might suggest similar level trends. Augurin levels were significantly lower in SAH patients, but we found no significant difference between good and poor outcome patients, nor did we find significant changes with time. Synaptotagmin-11 regulates repair of injured astrocytes following acute brain injury [33] and also suppresses microglial activation under both physiological and pathological conditions, through the inhibition of cytokine secretion and phagocytosis [34] .
In this study, synaptotagmin-11 was found to be decreased in good outcome patients compared with healthy controls, but there was no significant difference between the good and poor outcome group. This raises the possibility that synaptotagmin-11 may have a protective role. Complement C3 is an essential immune regulator of host defence against infection, cell integrity, and tissue homeostasis in the peripheral system. It is a significant mediator of cerebral injury following stroke [31] . Administration of a C3areceptor antagonist resulted in commensurate neurological improvement and reduction of stroke volume in an animal model [35] .
Complement C3 is produced by astroglia if a proinflammatory signalling pathway (involving NF-kB) is employed [36] . If levels for all three sampling days are compared, the levels are significantly greater in poor outcome patients than in good outcome patients and controls; if day one is taken separately, the good outcome patients had significantly lower levels than the poor outcome group. Another protein we found to be elevated was angiotensinogen; this is a moderately abundant glycoprotein which is the precursor to angiotensin peptides and is the only known naturally occurring renin substrate. It is also synthesized by astrocytes [37] . The rat angiotensinogen (rAT) gene, which codes for the protein precursor, is known to be rapidly induced in rat liver in the course of the acute phase response [38] . It was found to be significantly elevated in good outcome patients compared to the poor group on the first day post-SAH. Secretogranin is an acidic secretory protein in large dense-core vesicles of neural and neuroendocrine tissues [39] . It is an established ischaemia-induced gene product [40] , but very little literature is available regarding its role. On day one post-SAH its level was significantly elevated in poor outcome patients. Complement C3, angiotensinogen and secretogranin levels in 
Limitations
This research is clearly a preliminary study. 
